CompletedNot Applicable

Use of Macrolides in Acute Chest Syndrome: A Multicenter Retrospective Study

France250 participantsStarted 2023-06-01

Plain-language summary

This study looks at whether using macrolide antibiotics is helpful and safe in treating acute chest syndrome, a serious complication in people with sickle cell disease. It reviews past cases from three hospitals where patients were treated in intensive care. The goal is to understand if macrolides make a difference, what germs are involved, how useful lab tests are, and how well patients tolerate these antibiotics.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patient (≥18 years old). * Diagnosis of acute chest syndrome (ACS). * Hospitalized in an intensive care unit (ICU). * Microbiological sampling performed (e.g., multiplex PCR, sputum culture \[ECBC\], and/or Legionella urinary antigen test). * Received empiric antibiotic therapy including a macrolide. Exclusion Criteria: * Minor patient (\<18 years old). * Acute chest syndrome not requiring ICU admission. * Acute chest syndrome without any attempt at microbiological documentation.

What they're measuring

Duration of mechanical ventilation (in days) among patients with ACS treated with empiric macrolides

Timeframe: 28 days

Trial details

NCT IDNCT07037706

SponsorCentre Hospitalier de Saint-Denis

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Sickle Cell Disease trials